{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:20:51Z","timestamp":1790706051404,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-023-01078-z","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T04:01:15Z","timestamp":1680667275000},"page":"631-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The Clinical Effectiveness of Denosumab (Prolia\u00ae) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-6505","authenticated-orcid":false,"given":"Magdalena Ruth","family":"Moshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstance","family":"Nicolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Jenal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vreugdenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"2","key":"1078_CR1","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/8756-3282(92)90192-Y","volume":"13","author":"RP Heaney","year":"1992","unstructured":"Heaney RP (1992) The natural history of vertebral osteoporosis is low bone mass an epiphenomenon? Bone 13(2):S23-26","journal-title":"Bone"},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jbmr.5650050302","volume":"5","author":"JA Kanis","year":"1990","unstructured":"Kanis JA (1990) Osteoporosis and osteopenia. J bone mineral res 5:209\u2013211","journal-title":"J bone mineral res"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"S505","DOI":"10.1016\/8756-3282(95)00258-4","volume":"17","author":"BL Riggs","year":"1995","unstructured":"Riggs BL, Melton Iii L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:S505\u2013S511","journal-title":"Bone"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","volume":"119","author":"SL Bonnick","year":"2006","unstructured":"Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119:S25\u2013S31","journal-title":"Am J Med"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","volume":"194","author":"NE Lane","year":"2006","unstructured":"Lane NE (2006) Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194:S3-11","journal-title":"Am J Obstet Gynecol"},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","volume":"8","author":"K Naylor","year":"2012","unstructured":"Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8:379\u2013389","journal-title":"Nat Rev Rheumatol"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","volume":"18","author":"KL Stone","year":"2003","unstructured":"Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SRJJOB, Research M (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J bone and mineral res 18:1947\u20131954","journal-title":"J bone and mineral res"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF01623184","volume":"2","author":"C Cooper","year":"1992","unstructured":"Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285\u2013289","journal-title":"Osteoporos Int"},{"key":"1078_CR9","unstructured":"Natural Therapy Pages (2019) World Osteoporosis Day 2019. In: World Osteoporosis Day 2019. Natural Therapy Pages"},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jcem.87.4.8417","volume":"87","author":"S Khosla","year":"2002","unstructured":"Khosla S, Melton LJ 3rd, Riggs BL (2002) Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443\u20131450","journal-title":"J Clin Endocrinol Metab"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/bmj.39050.597350.47","volume":"333","author":"KE Poole","year":"2006","unstructured":"Poole KE, Compston JE (2006) Osteoporosis and its management. Bmj 333:1251\u20131256","journal-title":"Bmj"},{"key":"1078_CR12","unstructured":"Barry P, Aspray T, Briers K (2012) Osteoporosis: assessing the risk of fragility fracture (NICE Clinical Guidance 146. National Institute for Health and Care Excellence"},{"key":"1078_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"1078_CR14","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]","author":"WH Organization","year":"1994","unstructured":"Organization WH (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12889-015-1684-7","volume":"15","author":"J Darb\u00e0","year":"2015","unstructured":"Darb\u00e0 J, Kaskens L, P\u00e9rez-\u00c1lvarez N, Palacios S, Neyro JL, Rejas J (2015) Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study. BMC Public Health 15:324","journal-title":"BMC Public Health"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS (2009) Relation between fractures and mortality: results from the Canadian multicentre osteoporosis study. CMAJ 181:265\u2013271","journal-title":"CMAJ"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7 (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46\u201356","journal-title":"Eur J Rheumatol"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2474-14-10","volume":"14","author":"R Born","year":"2013","unstructured":"Born R, Zwahlen M (2013) Disparities in bone density measurement history and osteoporosis medication utilisation in Swiss women: results from the Swiss Health Survey 2007. BMC Musculoskelet Disord 14:10","journal-title":"BMC Musculoskelet Disord"},{"key":"1078_CR19","unstructured":"Bundesamt f\u00fcr Gesundheit (2021) Spezialit\u00e4tenliste. http:\/\/www.spezialitaetenliste.ch\/Default.aspx. Accessed 24 May 2021"},{"key":"1078_CR20","unstructured":"United Nations Department of Economic and Social Affairs (UN DESA), United Nations Conference on Trade and Development (UNCTAD), Economic Commission for Africa (UNECA), Economic Commission for Europe (UNECE), Economic Commission for Latin America and the Caribbean (UNECLAC) EaSCfAatPU, Economic and Social Commission for Western Asia (UNESCWA), report. UNWTOUactt (2022) World Economic Situation and Prospects 2022"},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1759720X18805759","volume":"10","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM (2018) New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 10:209\u2013223","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1078_CR22","first-page":"81","volume":"14","author":"F Livio","year":"2018","unstructured":"Livio F (2018) Pharmacovigilance update. Rev Med Suisse 14:81\u201384","journal-title":"Rev Med Suisse"},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"1078_CR24","unstructured":"World Health Organization (2020) List of Member States by WHO Region and Mortality Stratum. In: Cost effectiveness and strategic planning (WHO-CHOICE). World Health Organization"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1037\/h0031619","volume":"76","author":"JL Fleiss","year":"1971","unstructured":"Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378","journal-title":"Psychol Bull"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int 103:44\u201349","journal-title":"Calcif Tissue Int"},{"key":"1078_CR27","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang Y-C, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"1078_CR28","unstructured":"Ankit Rohatgi (2020) WebPlotDigitizer. https:\/\/automeris.io\/WebPlotDigitizer\/. Accessed 8 Feb 2020"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2288-13-2","volume":"13","author":"K Thorlund","year":"2013","unstructured":"Thorlund K, Thabane L, Mills EJ (2013) Modelling heterogeneity variances in multiple treatment comparison meta-analysis\u2014are informative priors the better solution? BMC Med Res Methodol 13:2","journal-title":"BMC Med Res Methodol"},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285\u2013299","journal-title":"Res Synth Methods"},{"key":"1078_CR32","doi-asserted-by":"publisher","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, et al (2019) BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol 19(1):196. https:\/\/doi.org\/10.1186\/s12874-019-0829-2","DOI":"10.1186\/s12874-019-0829-2"},{"key":"1078_CR33","unstructured":"Higgins JPT, J.; Chandler, J.; Cumpston, M.; Li, T; Page, M.J.; Welch, V.A. (editors) (2020) Imputing standard deviations for changes from baseline. https:\/\/handbook-5-1.cochrane.org\/chapter_16\/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm"},{"key":"1078_CR34","first-page":"13","volume":"1992","author":"M Bracken","year":"1992","unstructured":"Bracken M (1992) Statistical methods for analysis of effects of treatment in overviews of randomized trials. Effective care of the newborn infant. 1992:13\u201320","journal-title":"Effective care of the newborn infant"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/2041-210X.12472","volume":"7","author":"MJ Lajeunesse","year":"2016","unstructured":"Lajeunesse MJ (2016) Facilitating systematic reviews, data extraction and meta-analysis with the metagear package for r. Methods Ecol Evol 7:323\u2013330","journal-title":"Methods Ecol Evol"},{"key":"1078_CR36","unstructured":"R Core Team (2020) R: A language and environment for statistical computing. In: Foundation for Statistical Computing, Vienna, Austria"},{"key":"1078_CR37","unstructured":"RStudio Team (2020) RStudio: Integrated Development for R. In:RStudio, Boston, USA"},{"key":"1078_CR38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:434\u2013455","journal-title":"J Comput Graph Stat"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Stat Sci 7:457\u2013472","journal-title":"Stat Sci"},{"key":"1078_CR40","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (2020) Cochrane Handbook for Systematic Reviews of Interventions version 6.1. Cochrane. https:\/\/training.cochrane.org\/handbook. Accessed Sep 2020","DOI":"10.1002\/9781119536604"},{"key":"1078_CR41","volume":"346","author":"E Mills","year":"2013","unstructured":"Mills E, Thorlund K, Ioannidis J (2013) Demystifying trial networks and network meta-analysis. BMJ (Clinical research ed) 346:f2914","journal-title":"BMJ (Clinical research ed)"},{"key":"1078_CR42","unstructured":"University of Cambridge, MRC Biostatistics Unit (n.d.) DIC: Deviance Information Criteria. http:\/\/www.mrcbsu.cam.ac.uk\/software\/bugs\/the-bugs-project-dic\/. Accessed Oct 2021"},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35","journal-title":"BMC Med Res Methodol"},{"key":"1078_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS ONE 8:e76654","journal-title":"PLoS ONE"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G (2012) Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 3:161\u2013176","journal-title":"Res Synth Methods"},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12891-017-1520-6","volume":"18","author":"JD Adachi","year":"2017","unstructured":"Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S (2017) Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskelet Disord 18:174","journal-title":"BMC Musculoskelet Disord"},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, Torring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J bone mineral res 28:746\u2013752","journal-title":"J bone mineral res"},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2474-11-130","volume":"11","author":"C Christiansen","year":"2010","unstructured":"Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD (2010) Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 11:130","journal-title":"BMC Musculoskelet Disord"},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J bone mineral res 33:190\u2013198","journal-title":"J bone mineral res"},{"key":"1078_CR51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","volume":"22","author":"TJ de Villiers","year":"2011","unstructured":"de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567\u2013576","journal-title":"Osteoporos Int"},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation I (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609\u20133617","journal-title":"J Clin Endocrinol Metab"},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene evaluation (MORE) investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","volume":"175","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM (2015) Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 175:913\u2013921","journal-title":"JAMA Intern Med"},{"key":"1078_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/jbmr.252","volume":"26","author":"A Itabashi","year":"2011","unstructured":"Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H, Gorai I, Sugimoto T, Mizunuma H, Ochi H, Constantine GD, Ohta H (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J bone mineral res 26:519\u2013529","journal-title":"J bone mineral res"},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.1644","volume":"27","author":"RM Jacques","year":"2012","unstructured":"Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal fracture trial (PFT). J J Bone Miner Res 27:1627\u20131634","journal-title":"J J Bone Miner Res"},{"key":"1078_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"1078_CR59","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","volume":"14","author":"H Morii","year":"2003","unstructured":"Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793\u2013800","journal-title":"Osteoporos Int"},{"key":"1078_CR61","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Shiraki M (2012) Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23:1131\u20131140","journal-title":"Osteoporos Int"},{"key":"1078_CR62","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","volume":"25","author":"MA Paggiosi","year":"2014","unstructured":"Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R (2014) Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 25:2729\u20132741","journal-title":"Osteoporos Int"},{"key":"1078_CR63","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/GME.0000000000000419","volume":"22","author":"S Palacios","year":"2015","unstructured":"Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, Brown JP, De Cicco NF, Williams R, Hines TL, Mirkin S, Chines AA, Bazedoxifene Study G (2015) A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause 22:806\u2013813","journal-title":"Menopause"},{"key":"1078_CR64","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/gme.0b013e318159f190","volume":"15","author":"S Palomba","year":"2008","unstructured":"Palomba S, Manguso F, Orio F Jr, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P (2008) Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 15:730\u2013736","journal-title":"Menopause"},{"key":"1078_CR65","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00198-005-1927-z","volume":"16","author":"S Palomba","year":"2005","unstructured":"Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanova L, Colao A, Doldo P, Mastrantonio P, Zullo F (2005) Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 16:1141\u20131149","journal-title":"Osteoporos Int"},{"key":"1078_CR66","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","volume":"23","author":"Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G","year":"2012","unstructured":"Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351\u2013363","journal-title":"Osteoporos Int"},{"key":"1078_CR67","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J bone mineral res: official J American Soc Bone Mineral Res 23:1923\u20131934","journal-title":"J bone mineral res: official J American Soc Bone Mineral Res"},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"JA Cauley","year":"2001","unstructured":"Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125\u2013134","journal-title":"Breast Cancer Res Treat"},{"key":"1078_CR69","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s001980200125","volume":"13","author":"E Siris","year":"2002","unstructured":"Siris E, Adachi JD, Lu Y, Fuerst T, Crans GG, Wong M, Harper KD, Genant HK (2002) Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. multiple outcomes of raloxifene evaluation. Osteoporos Int 13:907\u2013913","journal-title":"Osteoporos Int"},{"key":"1078_CR70","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00198-005-0028-3","volume":"17","author":"K Uusi-Rasi","year":"2006","unstructured":"Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575\u2013586","journal-title":"Osteoporos Int"},{"key":"1078_CR71","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","volume":"104","author":"S Dias","year":"2019","unstructured":"Dias S, Caldwell DM (2019) Network meta-analysis explained. Arch Dis Childhood - Fetal Neonatal Edition 104:F8","journal-title":"Arch Dis Childhood - Fetal Neonatal Edition"},{"key":"1078_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. Intern Emerg Med 12:103\u2013111","journal-title":"Intern Emerg Med"},{"key":"1078_CR73","unstructured":"European Medicines Agency (2006) Committee for Medicinal Products for Human Use (CHMP): Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-treatmentprimary-osteoporosis_en.pdf. Accessed 21 July 2021"},{"key":"1078_CR74","first-page":"413","volume":"28","author":"A Cranney","year":"2001","unstructured":"Cranney A, Welch V, Wells G, Adachi J, Shea B, Simon L, Tugwell P (2001) Discrimination of changes in osteoporosis outcomes. J Rheumatol 28:413\u2013421","journal-title":"J Rheumatol"},{"key":"1078_CR75","first-page":"9","volume":"9","author":"J Guralnik","year":"2020","unstructured":"Guralnik J, Bandeen-Roche K, Bhasin SAR, Eremenco S, Landi F, Muscedere J, Perera S, Reginster JY, Woodhouse L, Vellas B (2020) Clinically meaningful change for physical performance: perspectives of the ICFSR task force. J Frailty Aging 9:9\u201313","journal-title":"J Frailty Aging"},{"key":"1078_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081","journal-title":"Bone"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01078-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T14:52:19Z","timestamp":1729176739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01078-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":76,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01078-z","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Magdalena Moshi, Konstance Nicolopoulos, Danielle Stringer, Mathias Jenal, Ning Ma, Thomas Vreugdenburg has no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No informed consent was not required as this was secondary research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"informed consent"}}]}}